This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kao, S. J.
Right arrow Articles by Chow, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kao, S. J.
Right arrow Articles by Chow, J. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2000, p. 2876-2879, Vol. 44, No. 10
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Detection of the High-Level Aminoglycoside Resistance Gene aph(2")-Ib in Enterococcus faecium

Susan J. Kao,1 Il You,1 Don B. Clewell,2 Susan M. Donabedian,3 Marcus J. Zervos,3 Joanne Petrin,4 Karen J. Shaw,4,dagger and Joseph W. Chow1,*

Research and Medical Service, John D. Dingell VA Medical Center, and Wayne State University School of Medicine, Detroit, Michigan 482011; Departments of Biologic and Materials Sciences and Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan 481092; William Beaumont Hospital, Royal Oak, Michigan 480733; and Schering-Plough Research Institute, Kenilworth, New Jersey 070334

Received 22 December 1999/Returned for modification 6 March 2000/Accepted 17 July 2000


    ABSTRACT
Top
Abstract
Text
References

A new high-level gentamicin resistance gene, designated aph(2")-Ib, was cloned from Enterococcus faecium SF11770. The deduced amino acid sequence of the 897-bp open reading frame of aph(2")-Ib shares homology with the aminoglycoside-modifying enzymes AAC(6')-APH(2"), APH(2")-Ic, and APH(2")-Id. The observed phosphotransferase activity is designated APH(2")-Ib.


    TEXT
Top
Abstract
Text
References

High-level gentamicin resistance (MIC >=  500 µg/ml) in enterococci is predominantly mediated by aac(6')-Ie-aph(2")-Ia, which encodes the bifunctional aminoglycoside-modifying enzyme AAC(6')-APH(2") (10). Found less commonly is aph(2")-Id, another gene recently reported to be associated with high-level gentamicin resistance in enterococci (19). The presence of high-level gentamicin resistance in enterococci eliminates the synergistic killing usually seen when gentamicin is combined with a cell wall-active agent, such as ampicillin or vancomycin. aph(2")-Ic is a mid-level gentamicin resistance gene isolated infrequently from enterococci that eliminates the synergism between ampicillin and gentamicin, even though the gentamicin MIC for strains containing this gene is typically only ca. 256 µg/ml (4). We describe the cloning and sequencing of another aminoglycoside resistance gene, aph(2")-Ib, that is associated with high-level gentamicin resistance in Enterococcus faecium.

(This work was presented in part at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 28 September to 1 October 1997.)

Enterococci were identified by conventional biochemical criteria (9). E. faecium SF11770 is a blood culture isolate from a patient in Detroit, Mich. Escherichia coli DH5alpha and E. coli DH10b were used as recipients for electroporation and as hosts for maintaining recombinant plasmids. E. faecium GE1 (8) and Enterococcus faecalis FA2-2 (5) were the recipient strains in mating experiments. Gentamicin was obtained from Fluka (Buchs, Switzerland). Arbekacin and netilmicin were provided by Meiji Seika Kaisha (Tokyo, Japan). All other antimicrobial agents were purchased from Sigma Chemical Company (St. Louis, Mo.). Antimicrobial susceptibilities were determined by a standard broth microdilution method (15). Tests of synergistic killing were performed using a previously described method (12), with some modifications. Synergy was defined as a >= 2-log10 decrease in CFU/ml between the combination and its most active constituent after 24 h, with the number of surviving organisms in the presence of the combination being >= 2 log10 CFU/ml below the number of organisms in the starting inoculum. Also, at least one of the drugs must be present in a concentration that does not affect the growth curve of the test organism when used alone. One hundred twenty-one enterococcal clinical isolates (78 E. faecalis, 41 E. faecium, 1 Enterococcus raffinosus, and 1 Enterococcus gallinarum isolate) with high-level gentamicin resistance from separate patients in six Detroit, Mich., area hospitals were used to screen for the presence of the new gene. This collection included isolates that were part of clonal outbreaks in the Detroit area and had been previously screened for aph(2")-Id (19).

Plasmid DNA minipreparations and total genomic DNA were obtained by a modified alkaline lysis method (20). Methods for restriction endonuclease digestion, agarose gel electrophoresis of DNA, transformation by using calcium chloride or electroporation, and Southern blot hybridization were performed as previously described (2, 7, 19). The phosphocellulose paper binding assay was performed as previously described (4, 17). Oligonucleotide primers were synthesized by GIBCO BRL Life Technologies (Gaithersburg, Md.). The probes for aac(6')-Ie-aph(2")-Ia, aph(2")-Ic, and aph(2")-Id were prepared as described previously (4, 10, 19). DNA to be sequenced was obtained as described in the Qiagen (Chatsworth, Calif.) plasmid handbook. The vectors pBluescript II KS(+) (Stratagene Cloning Systems, La Jolla, Calif.) and pMW119 (Nippon Gene Corporation, Toyama, Japan) were used in standard cloning experiments (2). Nucleotide sequencing was performed at the DNA Sequencing Core, University of Michigan, Ann Arbor. Computer analysis was performed with MacVector software, version 6.0, and AssemblyLIGN, version 1.0.9 (Oxford Molecular Group, Oxford, United Kingdom). The GenBank database was searched with the BLAST program from the National Center for Biotechnology Information (1). Amino acid sequences were compared by using the Gap Analysis Program from the University of Wisconsin Genetics Computer Group (6). The PCR primers used for detecting the aac(6')-Ie-aph(2")-Ia gene were 5'-GAGCAATAAGGGCATACCAAAAATC-3' and 5'-CCGTGCATTTGTCTTAAAAAACTGG-3'. The primers for detecting aph(2")-Ib were 5'-TATGGATCCATGGTTAACTTGGACGCTGAG-3' and 5'-AT TAAGCTTCCTGCTAAAATATAAACATCTCTGCT-3'. The primers for detecting aph(2")-Ic were as previously reported (4). The primers for detecting aph(2")-Id were 5'-GGTGGTTTTTACAGGAATGCCATC-3' and 5'-CCCTCTTCATACCAATCCATATAACC-3'.

Aminoglycoside MICs for E. faecium SF11770 are shown in Table 1. The ampicillin MIC was 128 µg/ml, the streptomycin MIC was >2,000 µg/ml, and the vancomycin MIC was >256 µg/ml. The probes for the aac(6')-Ie-aph(2")-Ia, aph(2")-Ic, and aph(2")-Id genes did not hybridize to Southern blots of total cellular DNA from E. faecium SF11770. Filter matings, with SF11770 as the donor and E. faecium GE1 or E. faecalis FA2-2 as the recipient, did not result in the transfer of gentamicin resistance (the frequency was <1 × 10-9 per recipient CFU). Electroporation of a plasmid preparation from SF11770 into competent E. faecalis OG1RF cells also did not result in the selection of gentamicin-resistant transformants. In tests of bactericidal synergistic killing against E. faecium SF11770, ampicillin at 64 µg/ml combined with arbekacin at 8 or 16 µg/ml produced a 3- to 4-log10 decrease in CFU per milliliter at 24 h compared to the most active agent (ampicillin) (Fig. 1A and B). However, since the growth curve of the organism with either ampicillin or arbekacin alone was slightly different than the growth with no antimicrobial agent, this did not fulfill the strict criteria for synergistic killing. Ampicillin at 64 µg/ml combined with arbekacin at 2 or 4 µg/ml did not produce greater killing at 24 h than either drug alone (Fig. 1A and C). The combination of ampicillin (64 µg/ml) and gentamicin (16 µg/ml) also did not produce greater killing at 24 h than either drug alone (Fig. 1D).

                              
View this table:
[in this window]
[in a new window]
 
TABLE 1.   Susceptibilities of E. faecium SF11770, E. coli KHE5-2, and E. coli DH10b(pMW119) to aminoglycosides



View larger version (24K):
[in this window]
[in a new window]
 
FIG. 1.   Tests of synergistic killing against E. faecium SF11770. , no antimicrobial; open circle , ampicillin (64 µg/ml); black-down-triangle , arbekacin (16 µg/ml); down-triangle, ampicillin (64 µg/ml) plus arbekacin (16 µg/ml); , arbekacin (8 µg/ml); , ampicillin (64 µg/ml) plus arbekacin (8 µg/ml); black-lozenge , arbekacin (4 µg/ml); diamond , ampicillin (64 µg/ml) plus arbekacin (4 µg/ml); black-triangle, arbekacin (2 µg/ml); triangle , ampicillin (64 µg/ml) plus arbekacin (2 µg/ml); , gentamicin (16 µg/ml); and octagon , ampicillin (64 µg/ml) plus gentamicin (16 µg/ml).

Partial Sau3AI digestions of total genomic DNA from SF11770 were ligated to pBluescript II KS(+) digested with BamHI and dephosphorylated with calf intestine alkaline phosphatase. After electroporation of the ligated products, selection on Luria-Bertani plates containing 25 µg of gentamicin per ml yielded small numbers of gentamicin-resistant E. coli DH5alpha transformants. Additional subcloning experiments using HindIII and EcoRI and the low-copy-number vector pMW119 yielded a gentamicin-resistant E. coli DH10b transformant, designated KHE5-2, which contained a 1.5-kb cloned fragment. Aminoglycoside MICs for E. coli KHE5-2 and E. coli DH10b(pMW119) are shown in Table 1.

Nucleotide sequencing of the 1.5-kb fragment revealed the presence of an 897-bp open reading frame, with a G+C content of 32%, whose predicted amino acid sequence showed homology with sequences of aminoglycoside phosphotransferases deposited in GenBank. The highest homology was seen with the deduced proteins from the aph(2")-Id (32% identity and 49% similarity) and aac(6')-Ie-aph(2")-Ia genes (33% identity and 51% similarity with the APH(2")-Ia domain). Less closely related was the aph(2")-Ic gene (25% identity and 44% similarity). The gentamicin resistance gene has been designated aph(2")-Ib. The aminoglycoside phosphotransferase activity, designated APH(2")-Ib, was confirmed by the phosphocellulose paper binding assay. Crude extracts from E. coli KHE5-2 exhibited phosphotransferase activity with all of the aminoglycoside substrates listed in Table 1, except for neomycin. aph(2")-Ib was cloned by PCR into the shuttle vector pWM401 (20), the recombinant DNA was electroporated into competent E. faecalis JH2-2 cells (gentamicin MIC = 16 µg/ml), and high-level gentamicin-resistant (MIC > 2,000 µg/ml) E. faecalis transformants were obtained.

Evaluation of the presence of gentamicin resistance genes by PCR showed that 6 of 121 isolates (5%) were negative for the aac(6')-Ie-aph(2")-Ia, aph(2")-Ic, and aph(2")-Id genes. All six were positive for the aph(2")-Ib gene by PCR. These six isolates (five from blood and one from stool cultures) were all vancomycin-resistant E. faecium from three hospitals in Detroit, Mich., and five belonged to the same clonal group, as determined by pulsed-field gel electrophoresis. The gentamicin MICs for all six were >= 1,024 µg/ml, and the arbekacin MICs ranged from 8 to 32 µg/ml. All of the 121 isolates possessed one of the four gentamicin resistance genes tested, and none possessed more than one of the genes tested.

aph(2")-Ib is now the fourth aminoglycoside resistance gene detected in Enterococcus spp. that eliminates the bactericidal synergistic effect of ampicillin and gentamicin against enterococci. The origin of the aph(2")-I family of genes remains uncertain. aac(6')-Ie-aph(2")-Ia is also found in staphylococci and streptococci (18; M. Galimand, G. Gerbaud, P. Courvalin, and T. Lambert, Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 833, 1999), and it has been proposed that aac(6')-Ie-aph(2")-Ia was transmitted initially from staphylococci to enterococci (14). However, aph(2")-Ib, aph(2")-Ic, and aph(2")-Id have not yet been detected in staphylococci and thus are less likely to have been transmitted from staphylococci (21). When we compared the nucleic acid sequence of aph(2")-Ib to that of an unpublished aph(2") resistance gene from an E. coli clinical isolate from the former republic of Czechoslovakia (J. Petrin, R. Kuvelkar, M. Kettner, R. S. Hare, G. H. Miller, and K. J. Shaw, Cold Spring Harbor Bacteria Phage Meet., abstr. 197, 1995), we found that the two sequences were identical, except for four nucleotides (resulting in three amino acid changes). The 32% G+C content of aph(2")-Ib raises the possibility that this gene may have first originated in enterococci and then been transmitted to E. coli, since the G+C contents of Enterococcus spp. and E. coli are approximately 35 and 50%, respectively.

The aminoglycoside MIC profile of E. faecium SF11770 indicates various degrees of resistance to most of the clinically available aminoglycosides, except for arbekacin (Table 1). Arbekacin is a new aminoglycoside available in Japan, where it is used to treat gentamicin- and methicillin-resistant staphylococci (11, 13, 16). Although the combination of ampicillin and arbekacin at achievable concentrations in serum did not strictly fulfill the criteria for synergism against E. faecium SF11770, the combination with higher arbekacin concentrations did exhibit significantly greater killing of the organism than either agent alone. These preliminary findings need to be confirmed by in vivo data before arbekacin can be recommended for use in combination therapy against enterococci that possess aph(2")-Ib.

Nucleotide sequence accession number. The nucleotide sequence for aph(2")-Ib has been deposited in GenBank under accession number AF207840.


    ACKNOWLEDGMENTS

This study was supported in part by the Department of Veterans' Affairs.

We thank Haruyoshi Tomita, Stephen A. Lerner, and Sergei Vakulenko for helpful discussions, Liberty Chow for technical assistance, and Glenn W. Kaatz for help with Fig. 1.


    FOOTNOTES

* Corresponding author. Mailing address: Medical Service, John D. Dingell VA Medical Center, Detroit, MI 48201-1932. Phone: (313) 576-3310. Fax: (313) 576-1122. E-mail: aa2563{at}wayne.edu.

dagger Present address: RW Johnson Pharmaceutical Research Institute, San Diego, CA 92121.


    REFERENCES
Top
Abstract
Text
References

1. Altschul, S. F., W. Gish, W. Miller, E. W. Myers, and D. J. Lipman. 1990. Basic local alignment search tool. J. Mol. Biol. 215:403-410[CrossRef][Medline].
2. Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl. 1995. Current protocols in molecular biology, vol. 1. John Wiley & Sons, Inc., New York, N.Y.
3. Chow, J. W., S. M. Donabedian, D. B. Clewell, D. F. Sahm, and M. J. Zervos. 1998. In vitro susceptibility and molecular analysis of gentamicin-resistant enterococci. Diagn. Microbiol. Infect. Dis. 32:141-146[CrossRef][Medline].
4. Chow, J. W., M. J. Zervos, S. A. Lerner, L. A. Thal, S. M. Donabedian, D. D. Jaworski, S. Tsai, K. J. Shaw, and D. B. Clewell. 1997. A novel gentamicin resistance gene in Enterococcus. Antimicrob. Agents Chemother. 41:511-514[Abstract/Free Full Text].
5. Clewell, D. B., P. K. Tomich, M. C. Gawron-Burke, A. E. Franke, Y. Yagi, and F. Y. An. 1982. Mapping of Streptococcus faecalis plasmids pAD1 and pAD2 and studies relating to transposition of Tn917. J. Bacteriol. 152:1220-1230[Abstract/Free Full Text].
6. Devereux, J., P. Haeberli, and O. Smithies. 1984. A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res. 12:387-395.
7. Donabedian, S., J. W. Chow, D. M. Shlaes, M. Green, and M. J. Zervos. 1995. DNA hybridization and contour-clamped homogeneous electric field electrophoresis for identification of enterococci to the species level. J. Clin. Microbiol. 33:141-145[Abstract/Free Full Text].
8. Eliopoulos, G. M., C. Wennersten, S. Zighelboim-Daum, E. Reiszner, D. Goldmann, and R. C. Moellering, Jr. 1988. High-level resistance to gentamicin in clinical isolates of Streptococcus (Enterococcus) faecium. Antimicrob. Agents Chemother. 32:1528-1532[Abstract/Free Full Text].
9. Facklam, R. R., and M. D. Collins. 1989. Identification of Enterococcus species isolated from human infections by a conventional test scheme. J. Clin. Microbiol. 27:731-734[Abstract/Free Full Text].
10. Ferretti, J. J., K. S. Gilmore, and P. Courvalin. 1986. Nucleotide sequence analysis of the gene specifying the bifunctional 6'-aminoglycoside acetyltransferase 2"-aminoglycoside phosphotransferase enzyme in Streptococcus faecalis and identification and cloning of gene regions specifying the two activities. J. Bacteriol. 167:631-638[Abstract/Free Full Text].
11. Hotta, K., C. B. Zhu, T. Ogata, A. Sunada, J. Ishikawa, and S. Mizuno. 1996. Enzymatic 2"-N-acetylation of arbekacin and antibiotic activity of its product. J. Antibiot. 49:458-464[Medline].
12. Knapp, C., and J. A. Moody. 1992. Tests to assess bactericidal activity. Part 3. Time-kill assay for determining synergy, p. 5.16.21-5.16.29. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook, vol. 1. American Society for Microbiology, Washington, D.C.
13. Kondo, S., A. Tamura, S. Gomi, Y. Ikeda, T. Takeuchi, and S. Mitsuhashi. 1993. Structures of enzymatically modified products of arbekacin by methicillin-resistant Staphylococcus aureus. J. Antibiot. 46:310-315[Medline].
14. Murray, B. E. 1998. Diversity among multidrug-resistant enterococci. Emerg. Infect. Dis. 4:37-47[Medline].
15. National Committee for Clinical Laboratory Standards. 1997. Approved standard M7-A4. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. National Committee for Clinical Laboratory Standards, Wayne, Pa.
16. Osakabe, Y., Y. Takahashi, and K. Narihara. 1996. The utility and dosage and administration of arbekacin in patients with MRSA infection. Antibiot. Chemother. 12:120-127.
17. Perlin, M. H., and S. A. Lerner. 1979. Amikacin resistance associated with a plasmid-borne aminoglycoside phosphotransferase in Escherichia coli. Antimicrob. Agents Chemother. 16:598-604[Abstract/Free Full Text].
18. Rouch, D. A., M. E. Byrne, Y. C. Kong, and R. A. Skurray. 1987. The aacA-aphD gentamicin and kanamycin resistance determinant of Tn4001 from Staphylococcus aureus: expression and sequence analysis. J. Gen. Microbiol. 133:817-822.
19. Tsai, S. F., M. J. Zervos, D. B. Clewell, S. M. Donabedian, D. F. Sahm, and J. W. Chow. 1998. A new high-level gentamicin resistance gene, aph(2")-Id, in Enterococcus spp. Antimicrob. Agents Chemother. 42:1229-1232[Abstract/Free Full Text].
20. Wirth, R., F. Y. An, and D. B. Clewell. 1986. Highly efficient protoplast transformation system for Streptococcus faecalis and a new Escherichia coli- S. faecalis shuttle vector. J. Bacteriol. 165:831-836[Abstract/Free Full Text].
21. You, I., R. Kariyama, M. J. Zervos, H. Kumon, and J. W. Chow. 2000. In-vitro activity of arbekacin alone and in combination with vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 36:37-41[CrossRef][Medline].


Antimicrobial Agents and Chemotherapy, October 2000, p. 2876-2879, Vol. 44, No. 10
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Toth, M., Frase, H., Chow, J. W., Smith, C., Vakulenko, S. B. (2010). Mutant APH(2'')-IIa Enzymes with Increased Activity against Amikacin and Isepamicin. Antimicrob. Agents Chemother. 54: 1590-1595 [Abstract] [Full Text]  
  • Young, P. G., Walanj, R., Lakshmi, V., Byrnes, L. J., Metcalf, P., Baker, E. N., Vakulenko, S. B., Smith, C. A. (2009). The Crystal Structures of Substrate and Nucleotide Complexes of Enterococcus faecium Aminoglycoside-2''-Phosphotransferase-IIa [APH(2'')-IIa] Provide Insights into Substrate Selectivity in the APH(2'') Subfamily. J. Bacteriol. 191: 4133-4143 [Abstract] [Full Text]  
  • Toth, M., Chow, J. W., Mobashery, S., Vakulenko, S. B. (2009). Source of Phosphate in the Enzymic Reaction as a Point of Distinction among Aminoglycoside 2''-Phosphotransferases. J. Biol. Chem. 284: 6690-6696 [Abstract] [Full Text]  
  • Chow, V. C. Y., Hawkey, P. M., Chan, E. W. C., Chin, M. L., Au, T. K., Fung, D. K. C., Chan, R. C. Y. (2007). High-Level Gentamicin Resistance Mediated by a Tn4001-Like Transposon in Seven Nonclonal Hospital Isolates of Streptococcus pasteurianus. Antimicrob. Agents Chemother. 51: 2508-2513 [Abstract] [Full Text]  
  • Weigel, L. M., Donlan, R. M., Shin, D. H., Jensen, B., Clark, N. C., McDougal, L. K., Zhu, W., Musser, K. A., Thompson, J., Kohlerschmidt, D., Dumas, N., Limberger, R. J., Patel, J. B. (2007). High-Level Vancomycin-Resistant Staphylococcus aureus Isolates Associated with a Polymicrobial Biofilm. Antimicrob. Agents Chemother. 51: 231-238 [Abstract] [Full Text]  
  • Aslangul, E., Massias, L., Meulemans, A., Chau, F., Andremont, A., Courvalin, P., Fantin, B., Ruimy, R. (2006). Acquired Gentamicin Resistance by Permeability Impairment in Enterococcus faecalis. Antimicrob. Agents Chemother. 50: 3615-3621 [Abstract] [Full Text]  
  • Chen, Y.-G., Qu, T.-T., Yu, Y.-S., Zhou, J.-Y., Li, L.-J. (2006). Insertion sequence ISEcp1-like element connected with a novel aph(2'') allele [aph(2'')-Ie] conferring high-level gentamicin resistance and a novel streptomycin adenylyltransferase gene in Enterococcus.. J Med Microbiol 55: 1521-1525 [Abstract] [Full Text]  
  • Gal, M.-F. C.-L., Thurston, L., Rich, P., Miao, V., Baltz, R. H. (2006). Complementation of daptomycin dptA and dptD deletion mutations in trans and production of hybrid lipopeptide antibiotics.. Microbiology 152: 2993-3001 [Abstract] [Full Text]  
  • Aslangul, E., Ruimy, R., Chau, F., Garry, L., Andremont, A., Fantin, B. (2005). Relationship between the Level of Acquired Resistance to Gentamicin and Synergism with Amoxicillin in Enterococcus faecalis. Antimicrob. Agents Chemother. 49: 4144-4148 [Abstract] [Full Text]  
  • Tenover, F. C., Weigel, L. M., Appelbaum, P. C., McDougal, L. K., Chaitram, J., McAllister, S., Clark, N., Killgore, G., O'Hara, C. M., Jevitt, L., Patel, J. B., Bozdogan, B. (2004). Vancomycin-Resistant Staphylococcus aureus Isolate from a Patient in Pennsylvania. Antimicrob. Agents Chemother. 48: 275-280 [Abstract] [Full Text]  
  • Bozdogan, B., Esel, D., Whitener, C., Browne, F. A., Appelbaum, P. C. (2003). Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 52: 864-868 [Abstract] [Full Text]  
  • Lopes, M. d. F. S., Ribeiro, T., Martins, M. P., Tenreiro, R., Crespo, M. T. B. (2003). Gentamicin resistance in dairy and clinical enterococcal isolates and in reference strains. J Antimicrob Chemother 52: 214-219 [Abstract] [Full Text]  
  • Vakulenko, S. B., Mobashery, S. (2003). Versatility of Aminoglycosides and Prospects for Their Future. Clin. Microbiol. Rev. 16: 430-450 [Abstract] [Full Text]  
  • Murdoch, D. R., Mirrett, S., Harrell, L. J., Donabedian, S. M., Zervos, M. J., Reller, L. B. (2003). Comparison of Microscan Broth Microdilution, Synergy Quad Plate Agar Dilution, and Disk Diffusion Screening Methods for Detection of High-Level Aminoglycoside Resistance in Enterococcus Species. J. Clin. Microbiol. 41: 2703-2705 [Abstract] [Full Text]  
  • Vakulenko, S. B., Donabedian, S. M., Voskresenskiy, A. M., Zervos, M. J., Lerner, S. A., Chow, J. W. (2003). Multiplex PCR for Detection of Aminoglycoside Resistance Genes in Enterococci. Antimicrob. Agents Chemother. 47: 1423-1426 [Abstract] [Full Text]  
  • Donabedian, S. M., Thal, L. A., Hershberger, E., Perri, M. B., Chow, J. W., Bartlett, P., Jones, R., Joyce, K., Rossiter, S., Gay, K., Johnson, J., Mackinson, C., Debess, E., Madden, J., Angulo, F., Zervos, M. J. (2003). Molecular Characterization of Gentamicin-Resistant Enterococci in the United States: Evidence of Spread from Animals to Humans through Food. J. Clin. Microbiol. 41: 1109-1113 [Abstract] [Full Text]  
  • Lee, H. K., Vakulenko, S. B., Clewell, D. B., Lerner, S. A., Chow, J. W. (2002). Mutations in the aph(2")-Ic Gene Are Responsible for Increased Levels of Aminoglycoside Resistance. Antimicrob. Agents Chemother. 46: 3253-3256 [Abstract] [Full Text]  
  • Vergis, E. N., Hayden, M. K., Chow, J. W., Snydman, D. R., Zervos, M. J., Linden, P. K., Wagener, M. M., Schmitt, B., Muder, R. R. (2001). Determinants of Vancomycin Resistance and Mortality Rates in Enterococcal Bacteremia: A Prospective Multicenter Study. ANN INTERN MED 135: 484-492 [Abstract] [Full Text]  
  • Chow, J. W., Kak, V., You, I., Kao, S. J., Petrin, J., Clewell, D. B., Lerner, S. A., Miller, G. H., Shaw, K. J. (2001). Aminoglycoside Resistance Genes aph(2")-Ib and aac(6')-Im Detected Together in Strains of both Escherichia coli and Enterococcus faecium. Antimicrob. Agents Chemother. 45: 2691-2694 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kao, S. J.
Right arrow Articles by Chow, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kao, S. J.
Right arrow Articles by Chow, J. W.